Crane Biosciences
Delaware
About Crane Biosciences
Crane Biosciences specializes in the development of innovative gene therapies using red blood cell-derived nanoparticles (RBCNPs). These therapies are designed to be invisible to the immune system, addressing a critical challenge in gene therapy by preventing immune system reactions. The company's approach aims to revolutionize the treatment of diseases caused by genetic mutations, potentially offering cures and improving the lives of millions. Crane Biosciences combines biotechnology expertise with AI to enhance the development of its gene therapies, focusing on making a significant impact on human health through scientific innovation.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $125.0K
- Funding stage: Seed
- Last round: Pre-Seed (Jun 2024)
- Website: cranebio.com
Industries & Categories
Biotechnology, Genetics, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/crane-biosciences-9397 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.